Unanswered Scientific Questions About Lp(a)

Introduction

Despite decades of research establishing Lp(a) as a cardiovascular risk factor, fundamental questions remain unanswered. The field awaits results from outcomes trials that will determine whether lowering Lp(a) reduces cardiovascular events. Beyond this central question, important scientific uncertainties persist about mechanisms, optimal treatment approaches, and which patients would benefit most.

This article examines the key unanswered questions in Lp(a) science. Understanding what remains unknown helps patients and physicians calibrate expectations and recognize the limits of current knowledge while emerging therapies undergo final testing.

Is Lp(a) causal or merely a marker?

The evidence supporting Lp(a) causality is strong but still awaits definitive proof from randomized intervention trials. Mendelian randomization studies use genetic variants as instrumental variables to test causal relationships. For Lp(a), these studies consistently show that genetic variants associated with higher Lp(a) are also associated with increased cardiovascular risk (Emdin et al., 2016). This pattern strongly suggests causality rather than mere correlation.

However, Mendelian randomization has limitations. Genetic variants might affect cardiovascular risk through mechanisms independent of Lp(a) (pleiotropy). Lifelong exposure to genetically determined Lp(a) differs from the effects of pharmacologically lowering Lp(a) in adulthood. The final confirmation requires demonstrating that therapeutic Lp(a) reduction prevents cardiovascular events in randomized trials.

The HORIZON and OCEAN(a) trials will provide this evidence. Positive results would confirm that Lp(a) is a causal, modifiable risk factor. Negative results would force reconsideration of the causal hypothesis, though interpretation would need to account for degree of Lp(a) lowering achieved and potential mechanistic differences between lifelong low Lp(a) and pharmacological reduction.

Do all Lp(a) particles confer equal risk?

Lp(a) particles vary substantially in size due to differing numbers of kringle IV type 2 repeats in the apolipoprotein(a) component. Smaller isoforms are associated with higher Lp(a) concentrations because the liver secretes them more efficiently. The question is whether particle size affects atherogenicity independent of concentration.

Current evidence suggests that molar concentration rather than isoform size is the primary determinant of risk (Gudbjartsson et al., 2019). Two patients with identical Lp(a) concentrations appear to face similar risk regardless of whether their particles are predominantly large or small. This finding supports therapeutic approaches focused on reducing particle number without concern for isoform-specific effects.

However, uncertainty remains. Small isoforms might have different properties beyond concentration effects. The oxidized phospholipid cargo might differ between isoforms. As therapies reduce Lp(a) to very low levels, residual particles of different sizes might have varying residual risk. These nuances await investigation in treatment contexts.

Will lowering Lp(a) regress existing plaque?

The ultimate hope for Lp(a)-lowering therapy is not just slowing progression but actually reversing established atherosclerosis. Plaque regression has been demonstrated with intensive LDL-lowering therapy in some imaging studies. Whether Lp(a) reduction produces similar effects is unknown.

Theoretical arguments support both directions. Lp(a) particles contribute to the lipid core of plaques, so reducing their deposition might allow gradual resorption. However, Lp(a) also promotes calcification and fibrosis, which might be less reversible. The oxidized phospholipids on Lp(a) drive inflammatory processes that might persist even after Lp(a) reduction (Capoulade et al., 2015).

Imaging substudies within outcomes trials might address this question. Serial coronary CT angiography or intravascular ultrasound could assess whether profound Lp(a) lowering stabilizes, slows, or reverses plaque progression. These endpoints, while not the primary trial outcomes, would inform mechanistic understanding.

Is there a point of diminishing returns for Lp(a) reduction?

RNA-targeted therapies can reduce Lp(a) by 80-95%, with some patients achieving near-undetectable levels. Whether this profound reduction provides proportionally greater benefit than more modest lowering is unknown. There might be threshold effects where most benefit is captured by achieving levels below a certain cutoff.

The genetic epidemiology suggests continuous benefit without clear threshold. Risk decreases progressively with lower Lp(a) across the population distribution. However, this observational relationship might not translate directly to therapeutic intervention. The marginal benefit of reducing Lp(a) from 20 nmol/L to 5 nmol/L might be smaller than reducing from 200 nmol/L to 50 nmol/L.

This question has practical implications for dosing strategies. If near-complete Lp(a) elimination is required for optimal benefit, maximal dosing would be indicated. If achieving levels below a threshold suffices, less intensive treatment might provide similar outcomes with potentially better tolerability or cost-effectiveness.

Does early Lp(a) exposure drive most risk?

Atherosclerosis develops over decades, with cumulative exposure to atherogenic lipoproteins determining plaque burden. For LDL cholesterol, early intervention provides greater lifetime risk reduction than later treatment at the same achieved level. The question is whether Lp(a) follows the same pattern.

If most Lp(a)-related damage occurs in youth and early adulthood, intervening in middle age might provide limited benefit regardless of how much Lp(a) is reduced. The plaque initiated by decades of elevated Lp(a) might have already established the trajectory toward clinical events. This possibility raises concerns about the outcomes trials, which enroll patients who have had elevated Lp(a) throughout their lives.

Conversely, ongoing Lp(a) elevation might continue driving plaque progression at any age. Reducing Lp(a) in middle-aged or older adults might slow progression and reduce events even if it can’t reverse historical damage. The outcomes trials will test whether mid-life intervention provides benefit, but questions about optimal timing for intervention will remain.

Can Lp(a)-related aortic stenosis be prevented or reversed?

The association between elevated Lp(a) and calcific aortic valve stenosis is well established. Genetic studies show that lower Lp(a) associates with reduced aortic stenosis risk (Emdin et al., 2016). Whether pharmacological Lp(a) lowering can prevent stenosis development or slow its progression is unknown.

Aortic valve calcification involves different mechanisms than arterial atherosclerosis, though overlapping pathways exist. The oxidized phospholipids carried by Lp(a) appear to promote valve calcification through effects on valve interstitial cells (Capoulade et al., 2015). If this mechanism is targeted by Lp(a) lowering, valve protection might be achievable.

Neither HORIZON nor OCEAN(a) include aortic stenosis as a primary or secondary endpoint. Detection of aortic stenosis effects would require long follow-up given the slow progression of valve disease. Answering this question might require dedicated trials or long-term observational follow-up of treated populations.

What is the role of Lp(a) in ischemic stroke specifically?

Lp(a) is associated with increased stroke risk, but the relationship appears weaker than for coronary events. The mechanisms differ: coronary events involve plaque rupture and thrombosis, while strokes have heterogeneous etiologies including cardioembolism, large artery atherosclerosis, small vessel disease, and others.

The prothrombotic properties of Lp(a) might be particularly relevant for atherothrombotic stroke subtypes. Lp(a)‘s plasminogen-like structure interferes with fibrinolysis, potentially promoting clot propagation (Tsimikas, 2017). Whether Lp(a) lowering preferentially reduces certain stroke subtypes is unknown.

The outcomes trials include stroke in composite endpoints but weren’t powered to detect effects on stroke specifically. Understanding Lp(a)‘s contribution to cerebrovascular disease might require additional studies with stroke-focused designs and careful subtype classification.

Are there Lp(a)-related risks beyond cardiovascular disease?

Lp(a) research has focused primarily on atherosclerotic cardiovascular disease and aortic stenosis. Whether elevated Lp(a) affects other organ systems or disease processes is largely unexplored. Theoretical possibilities exist based on Lp(a)‘s biological activities.

The inflammatory properties of oxidized phospholipids might contribute to systemic inflammation or organ-specific inflammatory diseases. The prothrombotic effects could influence venous thromboembolism risk. The lipid transport functions might affect tissues beyond arteries.

These speculative connections remain uninvestigated. The current focus on cardiovascular outcomes is appropriate given the strong existing evidence. As Lp(a)-lowering therapies enter widespread use, observational studies might reveal unexpected benefits or harms in non-cardiovascular domains.

How does Lp(a) interact with other genetic risk factors?

Cardiovascular risk is determined by multiple genetic and environmental factors. How Lp(a) interacts with other genetic risks, like polygenic risk scores for coronary disease or familial hypercholesterolemia mutations, affects individual risk prediction and potentially treatment response.

Additive models suggest that Lp(a) risk compounds with other genetic risks. Someone with both elevated Lp(a) and high polygenic risk faces greater danger than someone with either alone. Whether interactions are strictly additive or multiplicative affects absolute risk calculations and prioritization of interventions.

For patients with multiple genetic risk factors, understanding these interactions helps prioritize treatments. If Lp(a) risk and LDL risk are independent and additive, addressing both provides cumulative benefit. If they interact more complexly, treatment sequencing or intensity might need adjustment.

Will different Lp(a)-lowering mechanisms produce different outcomes?

Multiple approaches to lowering Lp(a) are in development: antisense oligonucleotides, small interfering RNA, and potentially future gene editing or small molecule approaches. Each mechanism might produce subtly different effects beyond the common outcome of reduced Lp(a) concentration.

ASO and siRNA differ in their duration of effect, potency, and potentially in how they affect Lp(a) particle processing and clearance. If residual Lp(a) particles after treatment differ in composition or properties depending on mechanism, clinical effects might vary. These possibilities remain theoretical pending head-to-head comparisons.

For patients, the practical question is whether choosing between approved therapies will matter beyond convenience and tolerability. If outcomes trials succeed for both platforms, confidence that Lp(a) lowering itself drives benefit would increase. Mechanism-specific effects would suggest more complex biology.

What explains Lp(a)‘s evolutionary persistence?

Apolipoprotein(a), the distinctive component of Lp(a), evolved only in humans, great apes, and oddly, hedgehogs. Its persistence in human populations suggests some beneficial function, yet contemporary evidence shows only harmful effects. This evolutionary puzzle remains unsolved.

Proposed beneficial roles include wound healing enhancement, infection defense through oxidized phospholipid binding, and thrombotic protection against bleeding. These benefits might have outweighed cardiovascular harm when human lifespans were shorter and trauma more common. In modern environments with longer lifespans and reduced infectious threats, the balance has shifted.

Understanding Lp(a)‘s evolutionary function could reveal unexpected consequences of profound Lp(a) lowering. If Lp(a) serves important roles in certain contexts, eliminating it might create unforeseen problems. The outcomes trials are designed to detect safety signals, but rare or context-specific harms might emerge only with broader use.

Conclusion

The unanswered questions in Lp(a) science highlight how much remains to be learned even as therapies approach approval. The central question, whether lowering Lp(a) reduces cardiovascular events, will be answered by ongoing trials. But secondary questions about optimal treatment intensity, patient selection, effects on different disease manifestations, and long-term safety will require years of additional research.

For patients with elevated Lp(a), this uncertainty creates both challenge and opportunity. The challenge is making decisions without complete information. The opportunity is that the field is advancing rapidly, with answers to many questions expected within the next few years.

Living with uncertainty is uncomfortable but unavoidable. The appropriate response combines informed action on what is known with intellectual humility about what remains unknown. Current treatment options address what can be modified today. Emerging therapies may soon expand options dramatically. Staying informed about developments ensures readiness to benefit from scientific progress as it occurs.